The important role of caspases in programmed neuronal death has been demonstrated in a variety of CNS disorders, including stroke. Caspase-3 is a major executioner caspase and has been identified as a key mediator of neuronal death in the acute stage of stroke. Acute inhibition of caspase-3 provides robust protection of neurons against ischemic and traumatic cell death. However, caspase-3 activation is also involved in a variety of biological processes that do not lead to cell death. Caspase-3 serves as a key endogenous component that negatively regulates neurogenesis after stroke. Caspase-3 inhibition may be a potential way to expand the brain's neurogenic capacity to repair damaged tissues after stroke.
Fig. 1. Increased expression of caspase-3 in the subventricular zone and the dentate gyrus during the period of stroke recovery. (Fan et al., 2014)
Based on the in vitro model of ischemic stroke through the oxygen-glucose deprivation (OGD) method, Ace Therapeutics offers highly sensitive and reliable in vitro caspase-3 activity assay services designed for stroke drug discovery. The assay quantifies apoptosis levels in living neuronal cells and enables the evaluation of potential stroke drugs.
Colorimetric Determination of Caspase-3 Activity
Ace Therapeutics's caspase-3 colorimetric activity assay service provides a simple and convenient method to determine the caspase activity of the recognition sequence DEVD.
Fluorometric Determination of Caspase-3 Activity
To assess caspase 3 activity, we use a fluorescent caspase-3 detection dye that specifically binds to the active caspase-3 enzyme.
Ace Therapeutics's in vitro caspase-3 activity assay provides customers with a powerful tool to analyze the exact role of caspase-3 in stroke and evaluate potential stroke drugs. If you are interested in our services, please do not hesitate to contact us!
We are committed to accelerating progress in stroke research and drug development.